Media centre

Press releases

15/02/2007

Antisoma plc reports half-year results

London, UK: 15 February 2007 Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces its interim financial information for the period ended 31 December 2006.

Highlights

AS1404

• Positive data from phase II trials
  • Median survival extended by 5 months in lung cancer
  • Positive initial findings in ovarian and prostate cancers
• Preparations ongoing for phase III trial in lung cancer
• Good progress in talks with potential marketing partners

AS1411

• Progressing to phase II trials in renal cancer and acute myeloid leukaemia (AML)
  • Phase I trial shows promising activity in renal cancer
  • Phase I trial provides further evidence for favourable safety profile
  • AS1411 demonstrates potency against cancer cells from AML patients

AS1409

• Renal cancer and melanoma selected as initial indications for phase I testing

Financial highlights

• £24.8 million net of expenses raised in oversubscribed placing
• Cash and liquid resources at 31 December 2006 of £33.6 million (31 December 2005: £23.6 million, 30 June 2006: £14.9 million)
• Operating loss for the six months ended 31 December 2006 of £7.8 million (six months ended 31 December 2005: £9.6 million)

Dr Barry Price, Chairman of Antisoma, said: “Antisoma ended 2006 on a high, having announced positive data from three phase II trials of AS1404 and completed an oversubscribed placing. In 2007 we look forward to further trial data, progression of four drugs to the next phase of development and the conclusion of a major licensing deal for AS1404.”

For further information please visit the Company’s web site at www.antisoma.com.

Enquiries:

Glyn Edwards Chief Executive Officer
Raymond Spencer Chief Financial Officer
Daniel Elger		+44 (0)7909 915 068
Director of Communications,
Antisoma plc
Mark Court, Lisa Baderoon, Rebecca Skye Dietrich		+44 (0)20 7466 5000
Buchanan Communications

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the Group's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

View the Chairman's report in PDF format (31 KB, opens a new browser window)

View the interim financial information in PDF format (28 KB, opens a new browser window)

This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free Adobe Acrobat Reader. For PDF accessibility help, visit Access Adobe. These links will open in a new browser window.